Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | SLO | ENG

Naslov:NSCLC molecular testing in Central and Eastern European countries
Avtorji:Ryška, Ales (Avtor)
Berzinec, Peter (Avtor)
Brčić, Luka (Avtor)
Čufer, Tanja (Avtor)
Dziadziuszko, Rafal (Avtor)
Gottfried, Maya (Avtor)
Kovalszky, Ilona (Avtor)
Olszewski, Włodzimierz (Avtor)
Oz, Buge (Avtor)
Plank, Lukas (Avtor)
Tímár, József (Avtor)
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo UKPBAG - Univerzitetna klinika za pljučne bolezni in alergijo Golnik
Povzetek:Background: The introduction of targeted treatments for subsets of non-small cell lung cancer (NSCLC) has highlighted the importance of accurate molecular diagnosis to determine if an actionable genetic alteration is present. Few data are available for Central and Eastern Europe (CEE) on mutation rates, testing rates, and compliance with testing guidelines. Methods: A questionnaire about molecular testing and NSCLC management was distributed to relevant specialists in nine CEE countries, and pathologists were asked to provide the results of EGFR and ALK testing over a 1-year period. Results: A very high proportion of lung cancer cases are confirmed histologically/cytologically (75-100%), and molecular testing of NSCLC samples has been established in all evaluated CEE countries in 2014. Most countries follow national or international guidelines on which patients to test for EGFR mutations and ALK rearrangements. In most centers at that time, testing was undertaken on request of the clinician rather than on the preferred reflex basis. Immunohistochemistry, followed by fluorescent in situ hybridization confirmation of positive cases, has been widely adopted for ALK testing in the region. Limited reimbursement is a significant barrier to molecular testing in the region and a disincentive to reflex testing. Multidisciplinary tumor boards are established in most of the countries and centers, with 75-100% of cases being discussed at a multidisciplinary tumor board at specialized centers. Conclusions: Molecular testing is established throughout the CEE region, but improved and unbiased reimbursement remains a major challenge for the future. Increasing the number of patients reviewed by multidisciplinary boards outside of major centers and access to targeted therapy based on the result of molecular testing are other major challenges.
Ključne besede:non-small-cell lung carcinoma, molecular diagnostic techniques, EGFR mutations, ALK rearrangements, Central Europe, Eastern Europe
Leto izida:2018
Založnik:Springer Nature
Izvor:Velika Britanija
UDK:616-006
ISSN pri članku:1471-2407
OceCobissID:2434324 Povezava se odpre v novem oknu
COBISS_ID:2048273521 Povezava se odpre v novem oknu
DOI:10.1186/s12885-018-4023-4 Povezava se odpre v novem oknu
Opombe:Soavtorji: Peter Berzinec, Luka Brcic, Tanja Cufer, Rafal Dziadziuszko, Maya Gottfried, Ilona Kovalszky, Włodzimierz Olszewski, Buge Oz, Lukas Plank in Jozsef Timar; Nasl. z nasl. zaslona; Opis vira z dne 12. 4. 2018;
Število ogledov:146
Število prenosov:53
Datoteke:URL URL - Predstavitvena datoteka, za dostop obiščite https://bmccancer.biomedcentral.com/track/pdf/10.1186/s12885-018-4023-4.pdf
 
Nadgradivo:BMC Cancer
BioMed Central
 
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
Avtorske pravice:© The Author(s). 2018
:
  
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.


Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:09.03.2018

Nazaj